David Micklem

6PUBLICATIONS
35CO-AUTHORS
BiomaterialsHaematological tumoursMolecular targetsCharacterisation of biological macromoleculesGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 26, 2025
Paratope mapping of tilvestamab, an anti-AXL function-blocking antibody, using high-throughput bacterial expression of secreted scFv-osmY fusion proteins.

Eleni Christakou, Petri Kursula, David Micklem

|Jul 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Kenneth Sooi, Tuan Zea Tan, Jae-Weon Kim

|Mar 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.

Sonja Loges, Michael Heuser, Jörg Chromik

|Dec 17, 2024
AXL-TBK1 driven AKT3 activation promotes metastasis.

Emily N Arner, Dina Alzhanova, Jill M Westcott

|Jul 12, 2024
In vivo turnover and biodistribution of soluble AXL: implications for biomarker development.

Olav Tenstad, Eleni Christakou, Linn Hodneland Nilsson

|Nov 19, 2021
Phosphatidylserine receptors enhance SARS-CoV-2 infection.

Dana Bohan, Hanora Van Ert, Natalie Ruggio

Pageof 1

Frequent Collaborators

3 joint publications

Petri Kursula

2 joint publications

Eleni Christakou

1 joint publications

Dana Bohan

1 joint publications

Hanora Van Ert